Prognostic factors in patients with locally advanced breast cancer treated with neoadjuvant taxane-anthracycline combination chemotherapy = Taxane-anthracycline combination regimen으로 선행 화학 요법을 시행한 국소 진행성 유방암 환자의 예후예측인자

다국어 초록 (Multilingual Abstract)

Purpose: The aim of this study is to evaluate the prognostic factors of the group who received neoadjuvant chemotherapy with a taxane-anthracycline combination regimen.
Methods: We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. 101 patients received neoadjuvant chemotherapy with docetaxel and doxorubicin, 46 patients received with epirubicin and paclitaxel. After curative surgery, adjuvant chemotherapy with the same regimen was performed. The adjuvant chemotherapy regimen was adjusted when the response to neoadjuvant chemotherapy was in disease progression.
Results: The disease free survival is 78% after 5 years and 71% after 10 years for good response group; the disease free survival is 23% in 5 years and 23% in 10 years for the no response group (P<0.001). The overall survival is 93% after 5 years and 90% after 10 years for the good response group; the overall survival is 47% after 5 years and 38% after 10 years for the no response group (P<0.001). 13 patients of 17 patients who to be appeared in complete response were triple negative for breast cancer.
Conclusion: In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy.

목차 (Table of Contents)

• INTRODUCTION
• METHODS
• RESULTS
• DISCUSSION
• REFERENCES